it could work also in the context of cold tumors like prostate cancer! The bad part, they think they will be ready for clinical trials in 2 years.
A new immuno-oncology approach is being developed to reprogram tumor cells into dendritic cells directly within the patient, bypassing traditional cell therapy challenges. This method aims to enhance tumor immunogenicity and remodel the tumor microenvironment, leading to personalized immune responses against cancer. The lead program, AT-108, has demonstrated strong anti-tumor effects in preclinical studies, particularly in hard-to-treat tumors.
nature.com/articles/d43747-...
“In mice, in-vivo reprogramming induced strong anti-tumor immunity, including complete responses in hard-to-treat, non-immunogenic tumors even in monotherapy settings. Less than 2% of induced cDC1s were sufficient to drive complete responses, supporting the strong functional specialization of the induced cell type. Dosing in the first week was sufficient to drive long-lasting and systemic immune responses, with complete responders remaining tumor free upon re-challenge at day 1601. ”